These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16161072)
1. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072 [TBL] [Abstract][Full Text] [Related]
2. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907 [TBL] [Abstract][Full Text] [Related]
4. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843 [TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496 [TBL] [Abstract][Full Text] [Related]
6. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights. Cheng HL; Wallis C; Shou Z; Farhat WA J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634 [TBL] [Abstract][Full Text] [Related]
7. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570 [TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions. Gaustad JV; Benjaminsen IC; Ruud EB; Rofstad EK J Magn Reson Imaging; 2007 Jul; 26(1):133-43. PubMed ID: 17659570 [TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187 [TBL] [Abstract][Full Text] [Related]
10. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393 [TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440 [TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates. Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. Graff BA; Benjaminsen IC; Brurberg KG; Ruud EB; Rofstad EK J Magn Reson Imaging; 2005 Mar; 21(3):272-81. PubMed ID: 15723369 [TBL] [Abstract][Full Text] [Related]
15. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging. Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291 [TBL] [Abstract][Full Text] [Related]
16. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. Su MY; Cheung YC; Fruehauf JP; Yu H; Nalcioglu O; Mechetner E; Kyshtoobayeva A; Chen SC; Hsueh S; McLaren CE; Wan YL J Magn Reson Imaging; 2003 Oct; 18(4):467-77. PubMed ID: 14508784 [TBL] [Abstract][Full Text] [Related]